Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trilaciclib - G1 Therapeutics

Next Previous
Drug Profile

Trilaciclib - G1 Therapeutics

Alternative Names: COSELA; G1T 28; G1T28-1

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator G1 Therapeutics
  • Developer Boehringer Ingelheim; G1 Therapeutics; Quantum Leap Healthcare Collaborative; Simcere Pharmaceutical Group
  • Class Amines; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Ketones; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Myelosuppression
  • Phase III Colorectal cancer; Small cell lung cancer; Triple negative breast cancer
  • Phase II Bladder cancer; Breast cancer; Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 29 Jan 2025 G1 Therapeutics terminates a phase II trial for Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (IV) due to reallocate resources to other ongoing trilaciclib clinical trials (NCT05113966)
  • 10 Dec 2024 Efficacy and adverse events data from a phase III trial in Triple negative breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 18 Sep 2024 G1 Therapeutics has been acquired by Pharmacosmos

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top